×

TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR

  • US 20160046724A1
  • Filed: 07/21/2015
  • Published: 02/18/2016
  • Est. Priority Date: 07/21/2014
  • Status: Active Grant
First Claim
Patent Images

1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said anti-BCMA binding domain comprises:

  • (i) a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any anti-BMCA heavy chain binding domain amino acid sequences listed in Table 1 or 16; and

    (ii) a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any anti-BMCA light chain binding domain amino acid sequences listed in Table 1 or 16.

View all claims
  • 10 Assignments
Timeline View
Assignment View
    ×
    ×